BF-3R (10MG)

BF-3R, the triple-incretin (GLP-1 + GIP + glucagon receptor) research analog from the retatrutide class, supplied by BioFusion as a vacuum-sealed lyophilized vial of 10mg for triple-receptor receptor-pathway research.

Research context

BF-3R is the retatrutide-class triple-incretin research analog, the next-generation incretin-research compound after the dual-incretin tirzepatide class. The triple-receptor agonist profile (GLP-1R + GIPR + GcgR) makes it a frequent inclusion in comparative-binding-affinity research and receptor-pathway-mapping studies.

Synthesis & documentation

Produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility. Each lot is verified for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), moisture (Karl Fischer), and counter-ion (ion chromatography). Compare with our BF-1S single-incretin reference and BF-2T dual-incretin reference for cross-class research panels.

Storage & handling

Lyophilized BF-3R is stable at −20 °C for the printed shelf life. After reconstitution, the standard 14-day-at-2-8 °C reference window applies; avoid freeze-thaw cycling.

Why BioFusion

Triple-incretin analogs are exceptionally difficult to synthesize correctly, sequence length, modification placement, and side-chain conjugation make low-purity by-products common. BioFusion verifies LC-MS molecular weight against the canonical retatrutide-class reference. Bulk discounts trigger at three+ vials; members save 25% on every order plus complimentary U.S. shipping for 365 days.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.